Shuna Wang, Ph.D.

Affiliations: 
2011 University of Virginia, Charlottesville, VA 
Area:
General Economics, Pharmacy, Commerce-Business Economics
Google:
"Shuna Wang"

Parents

Sign in to add mentor
Simon Anderson grad student 2011 UVA
 (Reputation and Entry Deterrence: A Structural Empirical Model of Fighting Brands in the U.S. Pharmaceutical Market.)
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Diab S, Yu M, Wang S. (2020) CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success? Journal of Medicinal Chemistry
Abdelaziz AM, Basnet SKC, Islam S, et al. (2019) Synthesis and evaluation of 2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione derivatives as Mnk inhibitors. Bioorganic & Medicinal Chemistry Letters
Khair NZ, Lenjisa JL, Tadesse S, et al. (2019) Discovery of CDK5 Inhibitors through Structure-Guided Approach. Acs Medicinal Chemistry Letters. 10: 786-791
Abdelaziz AM, Diab S, Islam S, et al. (2018) Discovery of N-phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine derivatives as potent Mnk2 inhibitors: design, synthesis, SAR analysis, and evaluation of in vitro anti-leukaemic activity. Medicinal Chemistry (Shariqah (United Arab Emirates))
Rahaman MH, Yu Y, Zhong L, et al. (2018) CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia. Investigational New Drugs
Philip S, Kumarasiri M, Teo T, et al. (2017) Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy? Journal of Medicinal Chemistry
Lenjisa JL, Tadesse S, Khair NZ, et al. (2017) CDK5 in oncology: recent advances and future prospects. Future Medicinal Chemistry
Diab S, Abdelaziz AM, Li P, et al. (2017) Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia. European Journal of Medicinal Chemistry. 139: 762-772
Tadesse S, Zhu G, Mekonnen LB, et al. (2017) A novel series of N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amines as highly potent CDK4/6 inhibitors. Future Medicinal Chemistry
Tadesse S, Yu M, Mekonnen LB, et al. (2017) Highly Potent, Selective and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinase 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis and Evaluation. Journal of Medicinal Chemistry
See more...